KR860001580B1 - 벤질아졸 유도체의 제조 방법 - Google Patents

벤질아졸 유도체의 제조 방법 Download PDF

Info

Publication number
KR860001580B1
KR860001580B1 KR8202102A KR820002102A KR860001580B1 KR 860001580 B1 KR860001580 B1 KR 860001580B1 KR 8202102 A KR8202102 A KR 8202102A KR 820002102 A KR820002102 A KR 820002102A KR 860001580 B1 KR860001580 B1 KR 860001580B1
Authority
KR
South Korea
Prior art keywords
compound
solvent
acid
imidazolyl
methylene chloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
KR8202102A
Other languages
English (en)
Korean (ko)
Other versions
KR830010079A (ko
Inventor
마사루 오가따
Original Assignee
요시도시 가즈오
시오노기 세이야꾸 가부시끼 가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 요시도시 가즈오, 시오노기 세이야꾸 가부시끼 가이샤 filed Critical 요시도시 가즈오
Publication of KR830010079A publication Critical patent/KR830010079A/ko
Application granted granted Critical
Publication of KR860001580B1 publication Critical patent/KR860001580B1/ko
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
KR8202102A 1981-05-14 1982-05-14 벤질아졸 유도체의 제조 방법 Expired KR860001580B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP72986/1981 1981-05-14
JP56072986A JPS57188570A (en) 1981-05-14 1981-05-14 Benzylazole derivative
JP72986 1981-05-14

Publications (2)

Publication Number Publication Date
KR830010079A KR830010079A (ko) 1983-12-26
KR860001580B1 true KR860001580B1 (ko) 1986-10-10

Family

ID=13505217

Family Applications (1)

Application Number Title Priority Date Filing Date
KR8202102A Expired KR860001580B1 (ko) 1981-05-14 1982-05-14 벤질아졸 유도체의 제조 방법

Country Status (16)

Country Link
US (1) US4430331A (enExample)
EP (1) EP0066144B1 (enExample)
JP (1) JPS57188570A (enExample)
KR (1) KR860001580B1 (enExample)
AU (1) AU554243B2 (enExample)
CA (1) CA1193255A (enExample)
DE (2) DE66144T1 (enExample)
DK (1) DK161317C (enExample)
ES (1) ES8303400A1 (enExample)
GB (1) GB2103600B (enExample)
HU (1) HU188059B (enExample)
IE (1) IE52989B1 (enExample)
IL (1) IL65735A (enExample)
NZ (1) NZ200471A (enExample)
PH (1) PH17989A (enExample)
ZA (1) ZA823207B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3343671A1 (de) * 1983-12-02 1985-06-20 Basf Ag, 6700 Ludwigshafen Aminopropanolderivate von substituierten 2-hydroxy-propiophenonen, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870726A (en) 1970-09-09 1975-03-11 Bayer Ag Derivatives of 3-azolylpropyne and processes for their preparation and use
CH584695A5 (en) * 1973-02-20 1977-02-15 Ciba Geigy Ag 3-amino-2-hydroxypropoxy substd. diazines and pyridines - with beta-adrenergic blocking or stimulating activity
SE7601713L (sv) * 1975-03-03 1976-09-06 Merck & Co Inc Nya, substituerad imidazoler
JPS5488268A (en) * 1977-10-19 1979-07-13 Wellcome Found Novel imidazole derivatives*their manufacture and medical composition
US4210653A (en) * 1978-06-27 1980-07-01 Merck & Co., Inc. Pyridyloxypropanolamines
JPS5951943B2 (ja) * 1978-08-21 1984-12-17 キツセイ薬品工業株式会社 新規なイミダゾ−ル誘導体
GB2041363B (en) * 1979-01-19 1982-10-06 Pfizer Ltd N-benzyl-imidazoles
DK157860C (da) * 1979-06-07 1990-07-30 Shionogi & Co Analogifremgangsmaade til fremstilling af benzylimidazolderivater samt farmaceutisk acceptable syreadditionssalte deraf
IE810250L (en) * 1980-02-11 1981-08-11 Berlex Lab N-(3-phenoxy-2-hydroxypropyl) benzimidazole -1-¹alkanamines.
CA1156661A (en) * 1980-02-25 1983-11-08 Hoffmann-La Roche Limited Phenoxy-aminopropanol derivatives

Also Published As

Publication number Publication date
KR830010079A (ko) 1983-12-26
EP0066144B1 (en) 1986-02-19
GB2103600B (en) 1985-01-09
DK161317C (da) 1991-12-30
EP0066144A3 (en) 1983-11-30
US4430331A (en) 1984-02-07
IE821134L (en) 1982-11-14
ES512151A0 (es) 1983-02-01
DK161317B (da) 1991-06-24
ZA823207B (en) 1983-03-30
NZ200471A (en) 1985-08-30
EP0066144A2 (en) 1982-12-08
DK216282A (da) 1982-11-15
HU188059B (en) 1986-03-28
ES8303400A1 (es) 1983-02-01
IE52989B1 (en) 1988-04-27
PH17989A (en) 1985-02-28
IL65735A0 (en) 1982-08-31
DE66144T1 (de) 1983-05-26
AU554243B2 (en) 1986-08-14
DE3269141D1 (de) 1986-03-27
GB2103600A (en) 1983-02-23
JPS57188570A (en) 1982-11-19
AU8318082A (en) 1982-11-18
JPS6325583B2 (enExample) 1988-05-26
IL65735A (en) 1986-04-29
CA1193255A (en) 1985-09-10

Similar Documents

Publication Publication Date Title
JPS6089474A (ja) モルフイナン誘導体，その製造方法，及び該化合物を含有する抗腫瘍剤
US4263304A (en) 7 H-indolo[2,3-c]isoquinolines
CA1256433A (en) 1,7-naphthyridine derivatives and medicinal preparations containing same
KR830002451B1 (ko) 이미다졸릴 비닐 에테르의 제조방법
US4261928A (en) 2-Benzoyl-8-(2-chloro-4-methoxyphenoxy)-1-phenyl-1-octanone
US4322418A (en) Substituted 1-(α-aminocarbonyl-benzyl)-3,4-dihydro-isoquinolines, compositions and use
KR860001580B1 (ko) 벤질아졸 유도체의 제조 방법
US5026712A (en) Novel imidazo[1,5-a]pyridines, useful as cardiovascular and CNS agents
EP0202760B1 (en) Carbostyril derivatives and salts thereof, processes for preparing the same and cardiotonic composition containing the same
US4124587A (en) 4-Hydroxy-3-sulfinyl-quinolin-2(1H)-ones
US4001271A (en) 3-(isopropyl amino alkoxy)-2-phenyl-isoindolin-1-ones
CA1265141A (en) 1-¬bis(hydroxymethyl)-methyl|-2-substituted- isoquinoline derivatives and pharmaceutical compositions containing them
EP0227100B1 (en) N-vinylimidazoles and -triazoles and pharmaceutical compositions containing them
US4340595A (en) Aminopropanol derivatives of 6-hydroxy-2,3,4,5-tetrahydro-1H-1-benzazepin-2-one and pharmaceutical formulations containing the said compounds
US4950677A (en) Benzimidazole derivative compounds and method of making
PL159840B1 (pl) dropirydyn PL PL
US4428950A (en) (Hetarylphenoxy)-(phenylpiperazinyl)-propanols, their preparation and drugs containing these compounds
GB2062637A (en) Imidazolylethoxy derivatives of quinoline-2-or 4-methanols
FI70013B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 4-lkyl-5-metyl-3-(omega-piperidinylalkoxi)pyrrol-2-karboxyl syaestrar
EP0272810A2 (en) Antitumor and antiviral alkaloids
US4590197A (en) 9,10-substituted 2-mesitylimino-3-alkyl-3,4,6,7-tetra-hydro-2H-pyrimido(6,1-a)isoquinolin-4-ones, and their use as medicaments
US4333935A (en) Antianxiety compositions of 10-hydroxy 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino-1,2a azepines and a method of use thereof
US4734428A (en) Aminoethylimidazole and cytoprotective and gastric antisecretory composition containing the same
GB1589752A (en) 5,6-dihydro-3-phenyl-imidazo(5,1-a)isoquinolines
KR102484696B1 (ko) 전기 분해 반응에 의한 디히드로퓨란 유도체의 합성 방법 및 이에 의해 합성된 디히드로퓨란 유도체

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 19951011

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 19951011

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301